No announcement yet.

CIDRAP - Daily News - Novel H1N1 Influenza (Swine Flu) SEPT 09

  • Filter
  • Time
  • Show
Clear All
new posts

  • CIDRAP - Daily News - Novel H1N1 Influenza (Swine Flu) SEPT 09

    #1: CIDRAP link:
    "Sep 3, 2009 (CIDRAP News)The Institute of Medicine (IOM) today affirmed existing federal guidance that healthcare workers caring for H1N1 influenza patients should wear fit-tested N95 respirators, not just surgical masks, to protect them from the virus.
    At the same time, the IOM called for additional research on flu transmission and the effectiveness of various respiratory protection tools in clinical settings, along with efforts to develop new respiratory protection technologies to enhance safety and comfort.
    "Based on what we currently know about influenza, well-fitted N95 respirators offer health care workers the best protection against inhalation of viral particles," said Kenneth Shine, chair of the committee that wrote the report, in an IOM news release."

    Finaly firm scientific standup media releases about the need of respirators for HCW to be best protected from viral particles inhalation.

    And obviously, that's mean the same protection will be gained by anyone else who wore it in a proper way.

  • #2
    Re: CIDRAP - Novel H1N1 Influenza (Swine Flu) News

    Thank you IOM.


    • #3
      Re: CIDRAP - Novel H1N1 Influenza (Swine Flu) News

      #1: Novartis vacc. link

      The "Disclaimer" text inner the "Novartis" adjuvanted cell vaccine link,
      is very interesting - a must read:

      "... These initial results should help to plan vaccination campaigns in the autumn, including doses and timings. We concluded that the MF59-adjuvanted A(H1N1) vaccine of low antigen content was well tolerated and generated antibody responses associated with protection against influenza, even after a single dose."


      The foregoing release contains forward-looking statements that can be identified by terminology such as "potentially," "to include," "will," "encouraging," "suggests," "may," "should," "plan", "or similar expressions, or by express or implied discussions regarding potential marketing approvals for an influenza A(H1N1) vaccine, potential production timing and volumes for such a vaccine or regarding potential future revenues from such a vaccine. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that influenza A(H1N1) vaccines will be approved for sale in any market. Nor can there be any guarantee that influenza A(H1N1) vaccines will be produced by any particular date, or in any particular volumes. Neither can there be any guarantee that influenza A(H1N1) vaccines will achieve any particular levels of revenue in the future. In particular, management's expectations could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data from the ongoing trials of the A(H1N1) vaccine, and unexpected additional analysis of existing clinical data regarding the vaccine; unexpected regulatory actions or delays or government regulation generally; unexpected manufacturing difficulties or delays, including unexpected difficulties with our flu cell culture manufacturing facility and processes, and unexpected difficulties with the established egg-based manufacturing process; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.